Vasif Kalfa, MD
Allergy & Immunology · Silver Spring, MDNPI 1376567735
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations.
Across 144 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$429
- GSK$391
- Regeneron Healthcare Solutions, Inc.$325
- AstraZeneca$295
- Novartis$282
- Takeda Pharmaceuticals U.S.A., Inc.$212
- plus $859 from 20 others
What the payments were for
- Food & beverage$2,60193%
- Education$1927%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 17 | $429 |
| GSK | 28 | $391 |
| Regeneron Healthcare Solutions, Inc. | 13 | $325 |
| AstraZeneca | 20 | $295 |
| Novartis | 16 | $282 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $212 |
| Galderma Laboratories, L.p. | 6 | $113 |
| Grifols USA, LLC | 4 | $107 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Pfizer | 4 | $66 |
| Biocryst US Sales Co., LLC | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Boehringer Ingelheim | 3 | $46 |
| Lilly USA, LLC | 2 | $45 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
| Alk-abello, Inc | 1 | $31 |
| Organon | 2 | $30 |
| Optinose US, Inc. | 2 | $29 |
| Bio Products Laboratory USA, Inc. | 2 | $26 |
| CSL Behring | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $22 |
| Circassia Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $17 |
| Greer Laboratories, Inc. | 1 | $17 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
How this compares
$2,793 in reported general payments places this provider in the 55th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 56 | $217,910 |
| Dupixent PenDupilumab | 46 | $171,974 |
| XolairOmalizumab | 34 | $95,199 |
| NucalaMepolizumab | 20 | $89,199 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $81,887 |
| Spiriva RespimatTiotropium Bromide | 28 | $21,839 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $17,852 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $16,186 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $16,135 |
| Arnuity ElliptaFluticasone Furoate | 25 | $8,227 |
| Montelukast Sodium | 614 | $7,720 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $7,510 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $7,396 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $6,646 |
| Epinephrine | 22 | $6,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $391 | $195,447170 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $295 | $34,03868 claims |
| Boehringer IngelheimSpiriva Respimat | $46 | $21,83928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 105 allergy & immunology providers in Maryland.
Other allergy & immunology in Silver Spring
- Angela CanadySilver Spring$15K
- Martin CorreaSilver Spring$8K
- Jenni YoonSilver Spring$3K
- Nkiruka ErekosimaSilver Spring$3K
- Djahna ThomasSilver Spring$2K
- Antoine AzarBaltimore$612K
- Mark ScarupaWheaton$508K
- Sally BaileyBaltimore$344K
- Manav SinglaWhite Marsh$168K
- Sudhir SekhsariaRockville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.